Jorge Zorzopulos
Overview
Explore the profile of Jorge Zorzopulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zorzopulos J, Opal S, Hernando-Insua A, Rodriguez J, Elias F, Flo J, et al.
World J Stem Cells
. 2017 Apr;
9(3):45-67.
PMID: 28396715
The immune responses of humans and animals to insults (., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation...
2.
Rodriguez J, Marchicio J, Lopez M, Ziblat A, Elias F, Flo J, et al.
PLoS One
. 2015 Feb;
10(2):e0117484.
PMID: 25706946
CD56+ cells have been recognized as being involved in bridging the innate and acquired immune systems. Herein, we assessed the effect of two major classes of immunostimulatory oligonucleotides (ODNs), PyNTTTTGT...
3.
Chahin A, Opal S, Zorzopulos J, Jobes D, Migdady Y, Yamamoto M, et al.
Antimicrob Agents Chemother
. 2014 Dec;
59(2):1225-9.
PMID: 25512413
IMT504 is a novel immunomodulatory oligonucleotide that has shown immunotherapeutic properties in early preclinical and clinical studies. IMT504 was tested in a neutropenic rat model of Pseudomonas aeruginosa bacteremia and...
4.
Franco R, Rodriguez J, Elias F, Hernando-Insua A, Flo J, Lopez R, et al.
Nucleic Acid Ther
. 2014 Apr;
24(4):267-82.
PMID: 24720569
IMT504 is a non-CpG 24-mer oligodeoxynucleotide (ODN) with immunomodulatory as well as tissue repair activity. IMT504 has been previously proven to be effective in animal models of vaccine potency, chronic...
5.
Montaner A, Denichilo A, Rodriguez J, Flo J, Lopez R, Pontoriero A, et al.
Nucleic Acid Ther
. 2011 Jul;
21(4):265-74.
PMID: 21793787
Flu vaccines are partially protective in infants and elder people. New adjuvants such as immunostimulatory oligonucleotides (ODNs) are strong candidates to solve this problem, because a combination with several antigens...
6.
Hernando-Insua A, Rodriguez J, Elias F, Flo J, Lopez R, Franco R, et al.
Oligonucleotides
. 2009 Dec;
20(1):33-6.
PMID: 19943802
Synthetic oligodeoxynucleotides (ODNs) are currently being evaluated as vaccine adjuvants for inducing protective immunity. As maternal vaccination is becoming increasingly common, the potential risk of vaccine formulation using ODN adjuvants...
7.
Hernando Insua A, Montaner A, Rodriguez J, Elias F, Flo J, Lopez R, et al.
Stem Cells
. 2007 Apr;
25(4):1047-54.
PMID: 17420228
Bone marrow (BM)-derived adult mesenchymal stem cells (MSCs) have the capacity to differentiate in vitro into different cell lines. This makes them a likely source for application in tissue repair...
8.
Rodriguez J, Elias F, Flo J, Lopez R, Zorzopulos J, Montaner A
Oligonucleotides
. 2006 Sep;
16(3):275-85.
PMID: 16978090
It is well known that synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG dinucleotides within a given context stimulate B lymphocytes and plasmacytoid dendritic cells (PDCs) of the vertebrate immune system. We...
9.
Rodriguez J, Elias F, Montaner A, Flo J, Lopez R, Zorzopulos J, et al.
Medicina (B Aires)
. 2006 Mar;
66(1):9-16.
PMID: 16555722
Oligonucleotides (ODNs) of the PyNTTTTGT class directly stimulate B lymphocytes and plasmacytoid dendritic cells of the immune system of primates. Here we investigated the ability of the PyNTTTTGT ODN prototype...
10.